Company intelligence / Profile preview

Synthland

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Synthland is an AI-native biotechnology company dedicated to revolutionizing drug discovery through generative artificial intelligence. The company develops advanced machine learning models to design novel small molecules and proteins with optimized pharmacological properties. By integrating computational design with automated laboratory validation, Synthland creates a high-velocity feedback loop to accelerate the development of next-generation therapeutics. Their approach aims to address challenging targets in oncology and other complex disease areas with high unmet medical needs.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeProtein
Industry: Biotech

Beyond the preview

Go deeper on Synthland.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synthland.

Explore the full profile